Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Samsung Bioepis

Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
From Samsung Bioepis
Via GlobeNewswire
FDA Approves Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab)
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
From Samsung Bioepis
Via GlobeNewswire
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara®
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
From Samsung Bioepis
Via GlobeNewswire
Tickers OGN
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16, a Proposed Biosimilar to Proliaⁱ (denosumab), at ASBMR 2023
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases Fourth Quarter 2023 US Biosimilar Market Report to Provide the Latest US Market Biosimilar Trends
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
From Samsung Bioepis
Via GlobeNewswire
Tickers OGN
Samsung Bioepis Releases its Second US Biosimilar Market Report
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases 2023 Sustainability Report
From Samsung Bioepis
Via GlobeNewswire
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis to Present New Data for SB15, a proposed biosimilar to Eylea (aflibercept), at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Releases its First US Biosimilar Market Report, Providing Insights on Pricing Trends and Usage Across Molecules
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab), A Proposed Biosimilar to Stelara, at 2023 AAD Annual Meeting
From Samsung Bioepis
Via GlobeNewswire
Samsung Bioepis Wins ‘Company of the Year, Asia-Pacific’ Award at the Global Generics & Biosimilars Awards 2022
From Samsung Bioepis
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.